AE	Adverse event
BID	Twice daily
CR	Complete response
DSB	Double-strand break
EM	Endometrium
EMCA	Endometrial cancer
EOC	Epithelial ovarian cancer
HGOC	High-grade ovarian cancer
HGSOC	High-grade serous ovarian cancer
HR	Hazard ratio
HRD	Homologous-recombination deficiency
HRP	Homologous-recombination proficiency
LOH	Loss of heterozygosity
NGS	Next-generation sequencing
OCCC	Ovarian clear cell carcinoma
ORR	Overall response rate
PARP	Poly(ADP-ribose) polymerase
PD-L1	Programmed death ligand 1
PFS	Progression-free survival
PR	Partial response
RCT	Randomized control trial
TIL	Tumor-infiltrating lymphocyte